BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 19476978)

  • 1. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.
    Erbersdobler A; Isbarn H; Steiner I; Schlomm T; Chun F; Mirlacher M; Sauter G
    Urology; 2009 Nov; 74(5):1169-73. PubMed ID: 19476978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.
    Sung MT; Lin H; Koch MO; Davidson DD; Cheng L
    Am J Surg Pathol; 2007 Feb; 31(2):311-8. PubMed ID: 17255778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
    Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
    Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
    Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.
    Mouraviev V; Sun L; Madden JF; Mayes JM; Moul JW; Polascik TJ
    Urology; 2007 Dec; 70(6):1141-5. PubMed ID: 18158035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative PSA is still predictive of cancer volume and grade in late PSA era.
    Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA
    Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
    Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
    Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies].
    Ojea Calvo A; Mosteiro Cerviño MJ; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; González Piñeiro A
    Arch Esp Urol; 2004 Oct; 57(8):805-16. PubMed ID: 15560269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
    Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
    Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
    Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
    Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence.
    Poulos CK; Koch MO; Eble JN; Daggy JK; Cheng L
    Cancer; 2004 Oct; 101(7):1563-8. PubMed ID: 15378493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
    Lee SE; Chung JS; Han BK; Park CS; Moon KH; Byun SS; Choe G; Hong SK
    Eur Urol; 2008 Dec; 54(6):1324-32. PubMed ID: 18339472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
    Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
    Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer.
    Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2007 Jul; 14(7):635-43. PubMed ID: 17645609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy.
    DeCastro GJ; McCann T; Benson MC; McKiernan JM
    Urology; 2008 Dec; 72(6):1214-8. PubMed ID: 18597825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of pathological stages before prostatectomy in prostate cancer patients: analysis of 12 systematic prostate needle biopsy specimens.
    Park EA; Lee HJ; Kim KG; Kim SH; Lee SE; Choe GY
    Int J Urol; 2007 Aug; 14(8):704-8. PubMed ID: 17681059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.